Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa

Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa

US Patent 9688645 · Granted Jun 27, 2017

Estimated economic value: $8,363,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and ste2022
Targeted cytotoxic ratjadone derivatives and conjugates thereof2022
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
1,4,7,10-tetrazacyclododecane based agents to target bacteria and its use2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020